SCHEMBL4144948

SCHEMBL4144948

O=C(O)C1=CC2(CCC1S(=O)(=O)Nc1ccc(Cl)cc1Cl)O[C@H](CO)[C@@H](CO)O2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 5/20 0.38
RAB9A P51151 3/20 0.35
MAPK1 P28482 1/20 0.34
UBE2M P61081 1/20 0.34
DCUN1D1 Q96GG9 1/20 0.34
NPC1 O15118 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
MCL1 Q07820 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
NPY1R P25929 1/20 0.32
NPY2R P49146 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
ATM Q13315 1/20 0.32
CNR2 P34972 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17727727 0.91 TLR4 (0.49) TLR4RAB9ANPC1ALDH1A1KMT2A
SCHEMBL4147605 0.91 TLR4 (0.41) TLR4MEN1MAPTKMT2ANAMPT
SCHEMBL4153824 0.91 TLR4 (0.36) TLR4NPC1MRGPRX1
SCHEMBL14136690 0.91 TLR4 (0.49) TLR4RAB9ANPC1ALDH1A1KMT2A
SCHEMBL4146514 0.91 TLR4 (0.49) TLR4RAB9ANPC1ALDH1A1KMT2A
SCHEMBL4141115 0.91 TLR4 (0.49) TLR4RAB9ANPC1ALDH1A1KMT2A
SCHEMBL17727700 0.88 PTK2B (0.35) TLR4RAB9ANPC1ALDH1A1TSHR
SCHEMBL4154931 0.88 PTK2B (0.35) TLR4RAB9ANPC1ALDH1A1TSHR
SCHEMBL1869580 0.87 TLR4 (0.53) TLR4RAB9AMAPK1UBE2MDCUN1D1
SCHEMBL4151008 0.83 ALDH1A1 (0.38) ALDH1A1TSHRMEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43858-E1 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
EP-1935879-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE CD40, LITAF, TNF TLR4 29/4885RAB9A 4610/4885MAPK1 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.